AMRI lays out $110M to buy Oso Biopharmaceuticals

Albany, NY-based contract developer and manufacturer AMRI ($AMRI) is upping its bet on sterile injectable drug manufacturing, agreeing to pay $110 million in cash to buy Oso Biopharmaceuticals Manufacturing. AMRI said the Albuquerque, NM-based Oso will expand its capabilities in small-molecule and biologics manufacturing. The deal, expected to close next quarter, will also provide about $3 million in cost synergies within a year. Story